Green Thumb Industries (GTBIF) Non-Current Deferred Tax Liability (2019 - 2026)
Green Thumb Industries (GTBIF) posted Non-Current Deferred Tax Liability of $220.6 million for Q1 2026, little changed on a QoQ basis from $220.6 million in Q4 2025, and up 180.58% year-over-year from $78.6 million in Q1 2025.
Green Thumb Industries (GTBIF) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Green Thumb Industries' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $220.6 million for Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 180.58% year-over-year to $220.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220.6 million (up 180.58% YoY) and the FY2025 annual result came in at $220.6 million, up 180.58% from the prior year.
- Non-Current Deferred Tax Liability was $220.6 million for Q1 2026 at Green Thumb Industries, roughly flat from $220.6 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $220.6 million in Q4 2025 and bottomed at $62.6 million in Q4 2022.
- A 5-year average of $90.6 million and a median of $78.6 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability slipped 23.58% — and 2025, when it jumped 180.58%.
- Green Thumb Industries' Non-Current Deferred Tax Liability stood at $62.6 million in 2022, then rose by 15.92% to $72.5 million in 2023, then increased by 8.43% to $78.6 million in 2024, then soared by 180.58% to $220.6 million in 2025, then changed by 0.0% to $220.6 million in 2026.
- Business Quant data shows GTBIF's Non-Current Deferred Tax Liability at $220.6 million in Q1 2026, $220.6 million in Q4 2025, and $78.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 220.60 Mn |
| Mar 31, 2026 | 220.60 Mn |
| Dec 31, 2025 | 220.60 Mn |
| Dec 31, 2025 | 220.60 Mn |
| Sep 30, 2025 | 78.62 Mn |
| Sep 30, 2025 | 78.62 Mn |
| Jun 30, 2025 | 78.62 Mn |
| Jun 30, 2025 | 78.62 Mn |
| Mar 31, 2025 | 78.62 Mn |
| Mar 31, 2025 | 78.62 Mn |
| Dec 31, 2024 | 78.62 Mn |
| Dec 31, 2024 | 78.62 Mn |
| Sep 30, 2024 | 72.51 Mn |
| Sep 30, 2024 | 72.51 Mn |
| Jun 30, 2024 | 72.51 Mn |
| Jun 30, 2024 | 72.51 Mn |
| Mar 31, 2024 | 72.51 Mn |
| Mar 31, 2024 | 72.51 Mn |
| Dec 31, 2023 | 72.51 Mn |
| Dec 31, 2023 | 72.51 Mn |